Protecting normal cells from the cytotoxicity of chemotherapy
Open Access
- 15 June 2012
- journal article
- Published by Informa UK Limited in Cell Cycle
- Vol. 11 (12), 2227
- https://doi.org/10.4161/cc.20961
Abstract
Comment on: van Leeuwen IMM, et al. Cell Cycle 2012; 11:1851-61Keywords
This publication has 7 references indexed in Scilit:
- An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cellsCell Cycle, 2012
- Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53Cell Death & Differentiation, 2010
- A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53Proceedings of the National Academy of Sciences of the United States of America, 2009
- Nongenotoxic p53 Activation Protects Cells against S-Phase–Specific ChemotherapyCancer Research, 2006
- Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic InhibitorsCancer Research, 2005
- UCN-01 dose-dependent inhibition of normal hyperproliferative cells in miceInternational Journal of Oncology, 2001
- Exploiting cancer cell cycling for selective protection of normal cells.2001